Have a feature idea you'd love to see implemented?
Let us know!
NVCT Nuvectis Pharma Inc
Price (delayed)
$4.9
Market cap
$94.67M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.16
Enterprise value
$77.5M
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock
Highlights
NVCT's EPS is up by 23% year-on-year and by 10% since the previous quarter
The net income has grown by 13% YoY and by 8% from the previous quarter
The equity has contracted by 34% YoY and by 12% from the previous quarter
NVCT's quick ratio is down by 31% year-on-year and by 13% since the previous quarter
Key stats
What are the main financial stats of NVCT
Market
Valuations
Earnings
Shares outstanding
19.32M
Market cap
$94.67M
Enterprise value
$77.5M
Price to earnings (P/E)
N/A
Price to book (P/B)
8.32
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$19.37M
EBITDA
-$19.37M
Free cash flow
-$13.63M
Per share
Balance sheet
Liquidity
EPS
-$1.16
Free cash flow per share
-$0.79
Book value per share
$0.59
Revenue per share
$0
TBVPS
$1
Total assets
$17.31M
Total liabilities
$6.32M
Debt
$0
Equity
$10.99M
Working capital
$10.99M
Debt to equity
0
Current ratio
2.74
Quick ratio
2.72
Net debt/EBITDA
0.89
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-104%
Return on equity
-155.8%
Return on invested capital
N/A
Return on capital employed
-176.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NVCT stock price
How has the Nuvectis Pharma stock price performed over time
Intraday
-3.35%
1 week
-14.49%
1 month
-36.28%
1 year
-39.66%
YTD
-41.25%
QTD
-22.1%
Financial performance
How have Nuvectis Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$20.26M
Net income
-$19.37M
Gross margin
N/A
Net margin
N/A
The net income has grown by 13% YoY and by 8% from the previous quarter
The operating income rose by 11% year-on-year and by 8% since the previous quarter
Growth
What is Nuvectis Pharma's growth rate over time
Valuation
What is Nuvectis Pharma stock price valuation
P/E
N/A
P/B
8.32
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NVCT's EPS is up by 23% year-on-year and by 10% since the previous quarter
The equity has contracted by 34% YoY and by 12% from the previous quarter
NVCT's P/B is 21% lower than its last 4 quarters average of 10.5
Efficiency
How efficient is Nuvectis Pharma business performance
The ROE has contracted by 11% YoY and by 2.3% from the previous quarter
The ROA has increased by 2.4% YoY and by 2.1% QoQ
Dividends
What is NVCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NVCT.
Financial health
How did Nuvectis Pharma financials performed over time
Nuvectis Pharma's total assets is 174% more than its total liabilities
NVCT's quick ratio is down by 31% year-on-year and by 13% since the previous quarter
Nuvectis Pharma's current ratio has decreased by 31% YoY and by 14% from the previous quarter
NVCT's debt is 100% lower than its equity
The equity has contracted by 34% YoY and by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.